PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97541596 |
Filing Date: 08/09/2022 |
Input Field |
Entered |
SERIAL NUMBER | 97541596 |
---|---|
MARK INFORMATION | |
*MARK | \\TICRS\EXPORT18\IMAGEOUT 18\975\415\97541596\xml1 \ APP0002.JPG |
SPECIAL FORM | YES |
USPTO-GENERATED IMAGE | NO |
LITERAL ELEMENT | KRAZATI |
COLOR MARK | NO |
*DESCRIPTION OF THE MARK (and Color Location, if applicable) |
The mark consists of the stylized term "KRAZATI". |
PIXEL COUNT ACCEPTABLE | NO |
PIXEL COUNT | 1079 x 250 |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | Mirati Therapeutics, Inc. |
*MAILING ADDRESS | 3545 Cray Court |
*CITY | San Diego |
*STATE (Required for U.S. applicants) |
California |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
92121 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Delaware |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors |
FILING BASIS | SECTION 1(b) |
INTERNATIONAL CLASS | 042 |
*IDENTIFICATION | research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals |
FILING BASIS | SECTION 1(b) |
ATTORNEY INFORMATION | |
NAME | Eric R. Moran |
ATTORNEY DOCKET NUMBER | 22-1287-US |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | McDonnell Boehnen Hulbert & Berghoff LLP |
INTERNAL ADDRESS | 31st Floor |
STREET | 300 South Wacker Drive |
CITY | Chicago |
STATE | Illinois |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 60606 |
PHONE | 312-913-0001 x3302 |
FAX | 312-913-0002 |
EMAIL ADDRESS | docketing@mbhb.com |
OTHER APPOINTED ATTORNEY | All other attorneys at McDonnell Boehnen Hulbert & Berghoff LLP |
CORRESPONDENCE INFORMATION | |
NAME | Eric R. Moran |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | docketing@mbhb.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | moran@mbhb.com; potempam@mbhb.com |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 2 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 700 |
*TOTAL FEES PAID | 700 |
SIGNATURE INFORMATION | |
SIGNATURE | /Eric R. Moran/ |
SIGNATORY'S NAME | Eric R. Moran |
SIGNATORY'S POSITION | Attorney of record, Illinois bar member |
SIGNATORY'S PHONE NUMBER | 312-913-3302 |
DATE SIGNED | 08/09/2022 |
SIGNATURE METHOD | Signed directly within the form |
PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97541596 |
Filing Date: 08/09/2022 |
The applicant's current Correspondence Information: |
Eric R. Moran |
PRIMARY EMAIL FOR CORRESPONDENCE: docketing@mbhb.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): moran@mbhb.com; potempam@mbhb.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|